Albumin News and Research

RSS

Predictors of bone metastasis, skeletal events in lung cancer identified

Researchers have identified a range of factors that are associated with the likelihood that a patient with advanced lung cancer will develop bone metastases or skeletal-related events.

20 Feb 2014

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Many vaccines, including those for influenza, polio, and measles, consist of a killed or disabled version of a virus. However, for certain diseases, this type of vaccine is ineffective, or just too risky.

18 Feb 2014

Novel method for determining diffusion coefficients of analytes in fluids and equilibrium constants of reactions

How strongly do two dissolved analytes react with each other? Such information is of paramount importance not only in chemistry and molecular biology, but also in medicine or pharmacy, where it is used, i.a., to determine optimal drug doses. A method developed in the Institute of Physical Chemistry of the Polish Academy of Sciences in Warsaw will allow for determining diffusion coefficients of analytes in fluids and equilibrium constants of reactions - quickly, at low cost, and most importantly: universally.

14 Feb 2014

Morning blood pressure tied to target-organ damage

Physicians should ask patients to take home blood pressure readings in the morning as well as the evening before making therapeutic decisions, say researchers.

3 Feb 2014

New data on extending the serum half-life of albumin in vivo announced by Novozymes Biopharma

...

27 Jan 2014

New study examines factors that may lead to end stage renal disease

About 33 percent of people with type 2 diabetes suffer kidney damage that progresses to end stage renal disease, at which point they require either dialysis or kidney transplantation. Scientists have thought that this kidney disease is driven by damage to the glomeruli, blood vessels in the kidney, which spill the protein albumin into the urine. Current treatments targeting the resulting "albuminuria" do not prevent kidney failure.

15 Jan 2014

Research findings provide insights into risks associated with isolated mild hyperglycemia

Despite having mild hyperglycemia for approximately 50 years, patients with a mutation in the gene encoding the enzyme glucokinase had a low prevalence of clinically significant vascular complications, findings that provide insights into the risks associated with isolated mild hyperglycemia, according to a study in the January 15 issue of JAMA.

15 Jan 2014

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Commission has granted approval for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, or metastatic pancreatic cancer.

7 Jan 2014

Co-culture with mesenchymal stem cells results in improved viability, function of human hepatocytes

Hepatocyte transplantation is becoming an accepted therapy for acute liver failure, either for liver regeneration or as a bridge to liver transplantation. However, maintaining the viability and functional aspects of hepatocytes has been a concern even with successful freezing.

19 Dec 2013

First Nations adults with diabetes more likely to face risk of end-stage kidney disease

First Nations adults with diabetes have more than double the risk of end-stage kidney disease compared with non-First Nations adults, found a new study in CMAJ (Canadian Medical Association Journal).

3 Dec 2013

Hypertension organ risk revealed in Chinese patients

A study of Chinese patients warns of the risk for target organ damage from untreated hypertension, especially for younger patients.

2 Dec 2013

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced that the European Medicines Agency's: Committee for Medicinal Products for Human Use has adopted a positive opinion for ABRAXANE (paclitaxel formulated as albumin bound nanoparticles, or nab-paclitaxel) in combination with gemcitabine for first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.

25 Nov 2013

Simple urine test can help identify disease risks in young type 1 diabetes patients

Using a simple urine test, researchers can now identify young people with type 1 diabetes at risk of heart and kidney disease. The new research, funded by JDRF, Diabetes UK, and the British Heart Foundation, was published today, 06 November, in the journal Diabetes Care.

7 Nov 2013

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Genkyotex, the leading developer of selective NOX enzyme inhibitors, announced today the initiation of a multinational Phase II clinical study of GKT137831 in patients with diabetic nephropathy.

5 Nov 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

23 Oct 2013

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

...

22 Oct 2013

Novozymes Biopharma partners with Almac to provide combined service for drug development

Novozymes Biopharma, part of Novozymes A/S, a world leader in bioinnovation, is delighted to announce its new collaboration with Almac, to provide a combined service for drug development applications in the field of drug targeting and pharmacokinetic improvements.

22 Oct 2013

Recombinant hormone could REPLACE calcium supplements

Results from the phase III REPLACE trial of recombinant human parathyroid hormone (rhPTH) indicate the treatment can successfully combat the underlying deficit in hypoparathyroidism.

18 Oct 2013

NEJM publishes Celgene’s Abraxane phase III study results

Published today in the New England Journal of Medicine, a phase III clinical trial of Abraxane (paclitaxel formulated as albumin-bound nanoparticles) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone [(median of 8.5 vs. 6.7 months) (HR 0.72, P=0.000015)].

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Albumin News and Research

Predictors of bone metastasis, skeletal events in lung cancer identified

New approach for delivering vaccines and for stimulating body's immune system to attack tumors

Novel method for determining diffusion coefficients of analytes in fluids and equilibrium constants of reactions

Morning blood pressure tied to target-organ damage

New data on extending the serum half-life of albumin in vivo announced by Novozymes Biopharma

New study examines factors that may lead to end stage renal disease

Research findings provide insights into risks associated with isolated mild hyperglycemia

EC grants approval for ABRAXANE in combination with gemcitabine for metastatic pancreatic cancer

Co-culture with mesenchymal stem cells results in improved viability, function of human hepatocytes

First Nations adults with diabetes more likely to face risk of end-stage kidney disease

Hypertension organ risk revealed in Chinese patients

CHMP adopts positive opinion for ABRAXANE with gemcitabine for treatment of metastatic pancreas

Simple urine test can help identify disease risks in young type 1 diabetes patients

Genkyotex announces initiation of GKT137831 Phase II study in patients with diabetic nephropathy

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

Novozymes, Almac Ally To Offer Drug Targeting, Pharmacokinetics Service

Novozymes Biopharma partners with Almac to provide combined service for drug development

Recombinant hormone could REPLACE calcium supplements

NEJM publishes Celgene’s Abraxane phase III study results

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News